Stocks and Investing
Stocks and Investing
Thu, May 16, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, May 15, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, May 14, 2019
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (SRPT) at Buy with Decreased Target to $165 on, May 14th, 2019
Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $169 to $165 on, May 14th, 2019.
Matthew has made no other calls on SRPT in the last 4 months.
There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Matthew
- Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $188 on, Thursday, May 9th, 2019
- Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $201 on, Friday, March 1st, 2019
- Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $231 on, Thursday, February 28th, 2019
- Christopher Marai of "Nomura" Maintained at Strong Buy with Increased Target to $230 on, Thursday, February 28th, 2019